[go: up one dir, main page]

EE9700225A - Meetod diabetes mellituse raviks, kasutades KKF - Google Patents

Meetod diabetes mellituse raviks, kasutades KKF

Info

Publication number
EE9700225A
EE9700225A EE9700225A EE9700225A EE9700225A EE 9700225 A EE9700225 A EE 9700225A EE 9700225 A EE9700225 A EE 9700225A EE 9700225 A EE9700225 A EE 9700225A EE 9700225 A EE9700225 A EE 9700225A
Authority
EE
Estonia
Prior art keywords
kkf
diabetes mellitus
treating diabetes
mammals
pharmaceutical compositions
Prior art date
Application number
EE9700225A
Other languages
English (en)
Inventor
Francis Pierce Glenn
Lea Aukerman Sharon
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of EE9700225A publication Critical patent/EE9700225A/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EE9700225A 1994-10-13 1995-10-12 Meetod diabetes mellituse raviks, kasutades KKF EE9700225A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32334094A 1994-10-13 1994-10-13
US32347594A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en) 1994-10-13 1995-10-12 Method of treating diabetes mellitus using kgf

Publications (1)

Publication Number Publication Date
EE9700225A true EE9700225A (et) 1998-02-16

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
EE9700225A EE9700225A (et) 1994-10-13 1995-10-12 Meetod diabetes mellituse raviks, kasutades KKF
EE9700081A EE03975B1 (et) 1994-10-13 1995-10-12 Keratinotsüüdi kasvufaktori analoogid

Family Applications After (1)

Application Number Title Priority Date Filing Date
EE9700081A EE03975B1 (et) 1994-10-13 1995-10-12 Keratinotsüüdi kasvufaktori analoogid

Country Status (23)

Country Link
EP (2) EP0804479B1 (et)
JP (2) JP4426646B2 (et)
KR (1) KR100278597B1 (et)
CN (1) CN1168678A (et)
AT (2) ATE342278T1 (et)
AU (1) AU3707795A (et)
BG (2) BG101392A (et)
BR (2) BR9509269A (et)
CA (2) CA2202075C (et)
CZ (3) CZ297329B6 (et)
DE (2) DE69530403T2 (et)
DK (2) DK0785948T3 (et)
EE (2) EE9700225A (et)
ES (2) ES2196082T3 (et)
FI (2) FI971420A (et)
HU (2) HUT78050A (et)
NO (2) NO318761B1 (et)
NZ (2) NZ505502A (et)
PL (2) PL182888B1 (et)
PT (2) PT804479E (et)
SI (2) SI0785948T1 (et)
SK (2) SK43197A3 (et)
WO (2) WO1996011950A1 (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153816T3 (es) 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
HUT73453A (en) 1993-06-29 1996-08-28 Chiron Corp A truncated keratinocyte growth factor /kgf/ having increased biological activity
SI0785949T1 (en) * 1994-10-13 2003-08-31 Amgen Inc. Method for purifying keratinocyte growth factors
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
AU5410196A (en) * 1995-04-27 1996-11-18 Cooperatie Suiker Unie U.A. Inulin derivatives
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
ES2218666T3 (es) * 1996-10-15 2004-11-16 Amgen Inc., Producto a base del factor de crecimiento de queratinocitos-2 (kggf-2).
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
CA2316015A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
WO2002062842A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gmbh Modified keratinocyte growth factor (kgf) with reduced immunogenicity
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
CA2457781A1 (en) 2001-08-21 2003-02-27 Chiron Corporation Kgf polypeptide compositions
JP5201992B2 (ja) 2004-12-15 2013-06-05 バイオビトラム・アクテイエボラーグ(パブリツク) ケラチノサイト増殖因子の治療用製剤
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd reg蛋白質
CA1306456C (en) * 1988-07-27 1992-08-18 Marjan International Pty. Ltd. Carpet stretcher
ES2153816T3 (es) * 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 bFGFムテインおよびその製造法
CN1064710C (zh) * 1993-03-26 2001-04-18 安姆根有限公司 角质细胞生长因子的治疗应用
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
HUT73453A (en) * 1993-06-29 1996-08-28 Chiron Corp A truncated keratinocyte growth factor /kgf/ having increased biological activity
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
EP0712314A1 (en) * 1993-08-02 1996-05-22 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
KR100278597B1 (ko) 2001-01-15
EP0785948A1 (en) 1997-07-30
BR9509269A (pt) 1997-12-23
CZ98197A3 (cs) 1998-11-11
PT785948E (pt) 2003-09-30
NO971568L (no) 1997-06-12
NO318761B1 (no) 2005-05-02
EE03975B1 (et) 2003-02-17
HUT78050A (hu) 1999-07-28
FI971420A0 (fi) 1997-04-04
SI0804479T1 (sl) 2006-12-31
FI971420A (fi) 1997-04-04
ES2196082T3 (es) 2003-12-16
SK284534B6 (sk) 2005-06-02
PT804479E (pt) 2007-02-28
NO971568D0 (no) 1997-04-04
EP0804479A1 (en) 1997-11-05
ES2273338T3 (es) 2007-05-01
DE69530403D1 (de) 2003-05-22
NZ335109A (en) 2000-08-25
FI120040B (fi) 2009-06-15
SK43197A3 (en) 1999-03-12
ATE342278T1 (de) 2006-11-15
NZ505502A (en) 2005-01-28
DK0785948T3 (da) 2003-08-04
HUT78058A (hu) 1999-07-28
EP0804479B1 (en) 2006-10-11
SI0785948T1 (en) 2003-08-31
CA2202075A1 (en) 1996-04-25
PL320484A1 (en) 1997-09-29
CZ297329B6 (cs) 2006-11-15
DE69530403T2 (de) 2003-10-30
CA2201940A1 (en) 1996-04-25
BG101408A (en) 1997-12-30
JP4216329B2 (ja) 2009-01-28
SK45597A3 (en) 1999-02-11
AU681546B2 (en) 1997-08-28
NO971566D0 (no) 1997-04-04
JPH10507193A (ja) 1998-07-14
CZ297328B6 (cs) 2006-11-15
WO1996011949A3 (en) 1996-12-12
AU3708395A (en) 1996-05-06
BG63167B1 (bg) 2001-05-31
PL182888B1 (pl) 2002-03-29
CZ105097A3 (cs) 1998-10-14
BG101392A (en) 1997-10-31
BR9509329A (pt) 1997-10-14
FI971536A0 (fi) 1997-04-11
DE69535264T2 (de) 2007-02-01
DK0804479T3 (da) 2007-01-29
EP0785948B1 (en) 2003-04-16
DE69535264D1 (de) 2006-11-23
JP4426646B2 (ja) 2010-03-03
PL319784A1 (en) 1997-08-18
AU3707795A (en) 1996-05-06
CA2201940C (en) 2009-05-12
FI971536A (fi) 1997-06-09
EE9700081A (et) 1997-10-15
CN1168678A (zh) 1997-12-24
JPH10507080A (ja) 1998-07-14
CA2202075C (en) 2003-12-09
HU226168B1 (en) 2008-05-28
ATE237633T1 (de) 2003-05-15
NO971566L (no) 1997-04-14
WO1996011950A1 (en) 1996-04-25
WO1996011949A2 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
AU5624699A (en) Use of 5ht-6 antagonists
BG102616A (en) Substituted aza- and diazacycloheptane and cyclooctane derivatives and their application
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
FR2491334B1 (et)
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE129712T1 (de) Substituierte pyrido-oxazine.
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
AU6826487A (en) Surgery for strengthening tendon in horses leg
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь